Pioneering an Era of Innovation and Exploring New Frontiers in Healthcare

“Within your gut resides a thriving metropolis of 100 trillion microbiota, where dysbiosis in the microbiome leads the way to chronic disease”
https://mylinbiotech.com/wp-content/uploads/2020/06/home_hero_detail.jpg
https://mylinbiotech.com/wp-content/uploads/2020/06/home_hero_detail.jpg
https://mylinbiotech.com/wp-content/uploads/2020/06/home_hero_detail.jpg
Hippocrates, the Father of Medicine, asserted that all diseases have their origins in the gut. Over time, the scientific community honed in on the pivotal role of Gut Dysbiosis in chronic illnesses.

Our unwavering commitment to excellence has transformed the landscape of research and manufacturing. Our mission is to substantially enhance the gut health of individuals, leaving a lasting impact on their well-being. We prioritise maintaining exceptional quality standards, a commitment that has led to patent applications in 56 countries including Europe, USA., Middle East countries, South Africa, Australia, Malaysia, Philippines, India and Sri Lanka. These innovations are then disseminated to healthcare professionals, who play a pivotal role in ensuring that our therapies reach those in need. We specialize in the seamless integration of research, manufacturing, and marketing, all aimed at improving the lives of patients afflicted with gut-related conditions. Our global recognition stands as a testament to the profound difference we make with our pioneering healthcare solutions.
bt_bb_section_top_section_coverage_image
bt_bb_section_bottom_section_coverage_image

Revolutionizing In

https://mylinbiotech.com/wp-content/uploads/2023/08/kidney.jpg

Nephrology

  • Pre-Dialysis
  • Dialysis
https://mylinbiotech.com/wp-content/uploads/2023/08/liver.jpg

Hepatology

  • Protein Energy Malnutrition in Liver Cirrhosis
  • IBS
https://mylinbiotech.com/wp-content/uploads/2023/08/critical-care-1.jpg

Critical Care

  • Cephalic Phase in RT & JT Feed
  • Antibiotic Associated Diarrhoea
https://mylinbiotech.com/wp-content/uploads/2023/08/cancer.jpg

Oncology

  • Anorexia
  • Sarcopenia
https://mylinbiotech.com/wp-content/uploads/2023/08/lungs.jpg

Pulmonology

  • Tuberculosis
  • Protein Energy
  • Malnutrition

Our Approach

Since our inception as a “research and innovation” organization in 2012, we have been on a relentless pursuit to overcome gut-mediated diseases. As a biotech company, we aspire to design a future where patients suffering from chronic kidney disease (CKD) and liver cirrhosis can look forward to healthier tomorrows.

At the intersection of biotech innovation and technology, our therapeutic approach revolves around synbiotics, enzobiotics, and enzotein research. This forms the cornerstone of future medical research, fostering a highly personalized healthcare paradigm that takes into account each individual’s unique hidden metabolic signature. With a dedicated vision to uncover these concealed metabolic markers within the intricate network of the gut’s 100 trillion microbiota, we recognize the profound impact of microbiota dysbiosis on quality of life and its role in various ailments. Our unwavering commitment drives us to pioneer evidence-based research, aimed at delivering tailored therapeutic solutions.

Over the last decade, we have been at the forefront of investigating the Gut-Kidney Axis, Gut-Brain Axis, and the Gut-Liver Axis, recognizing the pivotal role these play in understanding and managing gut-mediated diseases.

Conceptualization

https://mylinbiotech.com/wp-content/uploads/2023/10/govind-03-160x160.png
01. Conceptualization
Our ideating phase involves dedicated efforts in developing unique solutions to bolster healthcare for CKD and ESRD patients

Pre-Clinical

https://mylinbiotech.com/wp-content/uploads/2023/10/govind-08-160x160.png
02. Product Development
Here is where we transform concepts into tangible products through research and design
https://mylinbiotech.com/wp-content/uploads/2023/10/govind-09-160x160.png
03. Validation
Our products undergo thorough testing and verification to ensure superior quality, safety, and efficacy

Clinical

https://mylinbiotech.com/wp-content/uploads/2023/10/govind-05-160x160.png
04. Phase II
We conduct controlled studies to assess product effectiveness and safety in a larger group of participants
https://mylinbiotech.com/wp-content/uploads/2023/10/govind-06-160x160.png
05. Phase III
We gather additional data on product efficacy and side effects through a larger-scale clinical trial and comparing them with best currently available treatment options
https://mylinbiotech.com/wp-content/uploads/2023/10/govind-07-160x160.png
06. Phase IV
We then monitor the product’s performance and safety in real-world conditions after it is approved

Production

https://mylinbiotech.com/wp-content/uploads/2023/10/govind-04-160x160.png
07. Manufacturing
Large-scale production and quality control
processes are then executed to ensure
consistent and reliable product manufacturing

Explore the Science“All Diseases Begin in the Gut”

Hippocrates

Synbiotics

Derived from the Greek Word “probiotic,” meaning “for life,” probiotics are live microorganisms that benefit health when consumed in the right amounts. Prebiotics, on the other hand, support probiotic bacteria growth in the body. Synbiotics, a combination of both, play a therapeutic role in maintaining a healthy gastrointestinal tract. Notably, they reduce inflammatory markers like HSCRP, IL-6, and TNF-α . This makes them effective in managing conditions like uremic pruritus and Kyrle’s disease (KD), particularly in the context of chronic kidney disease (CKD) and uraemia. Synbiotics thus significantly enhance well-being through their profound gut health impact.

Enzobiotics

A special combination of synbiotics and proteolytic enzymes can effectively slow down the advancement of Chronic Kidney Disease (CKD) to higher stages. These compounds work by transforming the gut from a dysbiotic state to a healthy state, leading to a significant decrease in the generation of protein-bound uremic toxins PCS and IS. These toxins are biomarkers connected to a decline in kidney function. PCS (p-Cresol sulfate) and IS (Indoxyl sulfate) contribute to renal tubular damage by triggering free-radical production, upregulating nuclear factor (NF)-kB and PAI-1, and enhancing the expression of TGF Beta 1. Indoxyl sulfate also helps prevent Aortic Calcification and Vascular Stiffness. Enzobiotics not only significantly improve the quality of life but also show promise in preventing the progression of CKD to Cardiovascular Disease (CVD) by reducing PCS and IS.

Enzotein

Enzotein, a unique blend of proteolytic enzymes and low-dose protein supplements, effectively tackles protein energy malnutrition in economically disadvantaged end-stage renal disease (ESRD) patients. By enhancing protein breakdown and assimilation, Enzotein matches the nutritional and anti-inflammatory benefits of high-dose protein intake. This innovative combination excels at facilitating the efficient breakdown, assimilation, and absorption of proteins with an impressive PDCAAS value >1. This innovative approach can serve as a viable, cost-effective solution in resource-limited settings, promising to alleviate protein energy malnutrition and accelerate recovery, potentially shortening the healing process by 18 months for ESRD patients undergoing hemodialysis.

3
4
5
Trial
Trial (1)
Trial (2)